BeiGene
BGNE
#934
Rank
C$29.65 B
Marketcap
$266.55
Share price
-2.10%
Change (1 day)
-0.89%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -C$1.2 Billion

According to BeiGene 's latest financial reports the company's current earnings are C$3.09 Billion. In 2023 the company made an earning of -C$1.71 Billion, an increase over its 2022 earnings that were of -C$2.53 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -C$1.2 Billion-29.95%
2023 -C$1.71 Billion-32.52%
2022 -C$2.53 Billion24.39%
2021 -C$2.03 Billion-13.21%
2020 -C$2.34 Billion72.69%
2019 -C$1.36 Billion36.01%
2018 -C$1 Billion616.83%
2017 -C$0.14 Billion-15.24%
2016 -C$0.17 Billion107.91%
2015 -C$78.71 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$25.58 Million-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.35 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA